Skip to main content
Top
Published in: World Journal of Pediatrics 3/2020

01-06-2020 | Ribavirin | Viewpoint

Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019

Authors: Yan Wang, Li-Qin Zhu

Published in: World Journal of Pediatrics | Issue 3/2020

Login to get access

Excerpt

Up to now, no antiviral therapeutic regimens with exact efficacy are recommended to be used in children with coronavirus disease 2019 (COVID-19). Interim Guidance for Diagnosis and Treatment (the sixth edition) of COVID-19 [1] only provided potential antiviral treatments in adults. According to the current guidelines for management in adults and children and available resources in antiviral drugs, we herein discussed the pharmaceutical care of the five antiviral treatments (IFN-α, lopinavir/ritonavir, ribavirin, chloroquine diphosphate and arbidol) in children with COVID-19 (Table 1).
Table 1
Dosage regimen and precaution of antiviral drugs in children
Drugs
Age available
Dosage regimen of COVID-19 in children
Precaution/contraindication
IFN-α
Nebulization: using with caution in neonates and infants younger than 2 months
Nebulization: 200,000–400,000 IU/kg or 2–4 μg/kg in 2 mL sterile water, twice daily for 5–7 days
Spray: 1–2 sprays on each nostril and 8–10 sprays on the oropharynx, once every 1–2 h, 8–10 sprays/day for 5–7 days
Contraindication: CrCl < 50 mL/min; histories of mental illness, severe or unstable heart disease, or aplastic anemia
LPVr
China: OS ≥ 6 months, T ≥ 2 years
USA: OS ≥ 14 days, T ≥ 6 months
Body weight (kg)
 7–15: 12 mg/3 mg/kg/time, twice daily for 1–2 weeks
 15–40: 10 mg/2.5 mg/kg/time, twice daily for 1–2 weeks
 > 40: 400 mg/100 mg/time, twice daily for 1–2 weeks
Contraindication: patients with severe hepatic insufficiency
Not be recommended: children with jaundice
Ribavirin
China: oral dosage forms ≥ 6 years
USA and Europe: oral dosage forms ≥ 3 years
Intravenous infusion at a dose of 10 mg/kg every time (maximum 500 mg every time), 2–3 times daily
Not be recommended: CrCl < 50 mL/min
Should be discontinued: SCr > 2 mg/dL
Warning: hemolytic anemia
CD
Using with caution
No recommendation
Acute poisoning is usually fatal with a dose of 50 mg/kg
Arbidol
≥ 2 years for influenza in Russia
No recommendation
Using with caution in patients with liver dysfunction
IFN-α interferon-α, LPVr lopinavir/ritonavir, CD chloroquine diphosphate, COVID-19 coronavirus disease 2019, CrCl creatinine clearance, SCr serum creatinine, OS oral solutions, T tablets
Literature
2.
go back to reference Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–7.CrossRefPubMedPubMedCentral Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–7.CrossRefPubMedPubMedCentral
3.
go back to reference Shang XY, Huang Y, Liu EM, Chen Q, Cao L, Lu M, et al. A multicenter clinical study on the treatment for children's acute bronchiolitis by nebulized recombinant human interferon α1b. Chin J Pract Pediatr. 2014;29:840–4 (in Chinese). Shang XY, Huang Y, Liu EM, Chen Q, Cao L, Lu M, et al. A multicenter clinical study on the treatment for children's acute bronchiolitis by nebulized recombinant human interferon α1b. Chin J Pract Pediatr. 2014;29:840–4 (in Chinese).
4.
go back to reference Cui LD, Jin ZP, Wang Q, Cheng YB, Wang QS, PICU of Zhengzhou Children’s Hospital, et al. The effect of recombinant human interferon α1b combined with human normal immunoglobulin on serum cytokine and immunoglobulins levels in bronchiolitis children. Chin J Hosp Pharm. 2018;38:403–6 (in Chinese). Cui LD, Jin ZP, Wang Q, Cheng YB, Wang QS, PICU of Zhengzhou Children’s Hospital, et al. The effect of recombinant human interferon α1b combined with human normal immunoglobulin on serum cytokine and immunoglobulins levels in bronchiolitis children. Chin J Hosp Pharm. 2018;38:403–6 (in Chinese).
5.
go back to reference Zhong QL, Zheng YW, Yan JJ, Deng YF, Tang L, Cui ZL, et al. The contrast observation of the clinical efficacy and safety of interferon nebulization and ribavirin in the treatment of infantile herpes angina. Chin Med Pharm. 2017;7:80–2 (in Chinese). Zhong QL, Zheng YW, Yan JJ, Deng YF, Tang L, Cui ZL, et al. The contrast observation of the clinical efficacy and safety of interferon nebulization and ribavirin in the treatment of infantile herpes angina. Chin Med Pharm. 2017;7:80–2 (in Chinese).
6.
go back to reference Lin Y, Hu YY, Lin Z. Evaluation of efficacy and safety of interferon α2b spray for children with herpetic angina. J Pediatr Pharm. 2017;23:9–12 (in Chinese). Lin Y, Hu YY, Lin Z. Evaluation of efficacy and safety of interferon α2b spray for children with herpetic angina. J Pediatr Pharm. 2017;23:9–12 (in Chinese).
7.
go back to reference Lai CZ. Comparison of the efficacy of nebulized inhaled interferon and intramuscular injection of interferon in the treatment of hand, foot and mouth disease. Chin J Clin Ratio Drug Use. 2014;7:49–50 (in Chinese). Lai CZ. Comparison of the efficacy of nebulized inhaled interferon and intramuscular injection of interferon in the treatment of hand, foot and mouth disease. Chin J Clin Ratio Drug Use. 2014;7:49–50 (in Chinese).
8.
go back to reference Lin H, Huang L, Zhou J, Lin K, Wang H, Xue X, et al. Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double blind trial. Arch Virol. 2016;161:3073–80.CrossRefPubMed Lin H, Huang L, Zhou J, Lin K, Wang H, Xue X, et al. Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double blind trial. Arch Virol. 2016;161:3073–80.CrossRefPubMed
10.
go back to reference Shen KL, Shang YX, Zhang GC, Xu BP, Fu Z, Cao L, et al. Expert consensus on reasonable application of interferon in pediatrics. Chin J Appl Clin Pediatr. 2018;33:1301–8 (in Chinese). Shen KL, Shang YX, Zhang GC, Xu BP, Fu Z, Cao L, et al. Expert consensus on reasonable application of interferon in pediatrics. Chin J Appl Clin Pediatr. 2018;33:1301–8 (in Chinese).
11.
go back to reference Zhang GC, Shang YX. Expert consensus on clinical application of recombinant human interferon α1b in pediatrics. Chin J Appl Clin Pediatr. 2015;30:1220–2 (in Chinese). Zhang GC, Shang YX. Expert consensus on clinical application of recombinant human interferon α1b in pediatrics. Chin J Appl Clin Pediatr. 2015;30:1220–2 (in Chinese).
13.
go back to reference Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9:399–406.PubMed Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9:399–406.PubMed
14.
go back to reference Chong YP, Song JY, Seo YB, Choi JP, Shin HS, Rapid Response Team. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother. 2015;47:212–22.CrossRefPubMedPubMedCentral Chong YP, Song JY, Seo YB, Choi JP, Shin HS, Rapid Response Team. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother. 2015;47:212–22.CrossRefPubMedPubMedCentral
21.
go back to reference De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia-induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997–1004.CrossRefPubMed De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia-induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997–1004.CrossRefPubMed
22.
go back to reference Rao YH. Ribavirin-induced adverse drug reactions (ADRs): literature review of 182 cases. Eva Ana Drug Use Hosp Chin. 2007;4:52–6 (in Chinese). Rao YH. Ribavirin-induced adverse drug reactions (ADRs): literature review of 182 cases. Eva Ana Drug Use Hosp Chin. 2007;4:52–6 (in Chinese).
25.
go back to reference Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318:1–6.CrossRefPubMed Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318:1–6.CrossRefPubMed
26.
go back to reference Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Chin J Tubere Respir Dis. 2020;43:E019 (in Chinese). Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Chin J Tubere Respir Dis. 2020;43:E019 (in Chinese).
27.
go back to reference Haviernik J, Štefánik M, Fojtíková M, et al. Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018;10:E184.CrossRefPubMed Haviernik J, Štefánik M, Fojtíková M, et al. Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018;10:E184.CrossRefPubMed
29.
go back to reference Zhang J, Fang F. Research progress of non-nucleoside antiviral drug Arbidol. Chin J Evid Based Pediatr. 2011;6:308–12 (in Chinese). Zhang J, Fang F. Research progress of non-nucleoside antiviral drug Arbidol. Chin J Evid Based Pediatr. 2011;6:308–12 (in Chinese).
Metadata
Title
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019
Authors
Yan Wang
Li-Qin Zhu
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
World Journal of Pediatrics / Issue 3/2020
Print ISSN: 1708-8569
Electronic ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-020-00353-5

Other articles of this Issue 3/2020

World Journal of Pediatrics 3/2020 Go to the issue